首页> 外文OA文献 >Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer

【2h】

Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer

机译：随机CHER-LOB研究的前瞻性生物标志物分析，评估曲妥珠单抗和拉帕替尼联合化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Guarneri, Valentina; Dieci, Maria Vittoria; Frassoldati, Antonio; Maiorana, Antonino; Ficarra, Guido; Bettelli, Stefania; Tagliafico, Enrico; Bicciato, Silvio; Generali, Daniele Giulio; Cagossi, Katia; Bisagni, Giancarlo; Sarti, Samanta; Musolino, Antonino; Ellis, Catherine; Crescenzo, Rocco; Conte, Pierfranco;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer [J] . Guarneri Valentina, Dieci Maria Vittoria, Frassoldati Antonio, The oncologist . 2015,第9期

机译：随机CHER-LOB研究的前瞻性生物标记分析，评估曲妥珠单抗和拉帕替尼加化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗
2. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer [J] . Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, The oncologist . 2015,第9期

机译：随机CHER-LOB研究的前瞻性生物标记分析，评估曲妥珠单抗和拉帕替尼加化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗
3. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials [J] . Clavarezza Matteo, Puntoni Matteo, Gennari Alessandra, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第18期

机译：拉帕替尼和曲妥珠单抗与单药曲妥珠单抗联合化疗联合化疗作为HER2阳性乳腺癌新辅助治疗的随机对照试验的荟萃分析
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer [O] . Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, 2015

机译：随机CHER-LOB研究的前瞻性生物标记分析评估曲妥珠单抗和拉帕替尼加化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗
7. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer [O] . Guarneri, Valentina, Dieci, Maria Vittoria, Frassoldati, Antonio, 2015

机译：随机CHER-LOB研究的前瞻性生物标志物分析，评估曲妥珠单抗和拉帕替尼联合化学疗法作为HER2阳性乳腺癌新辅助疗法的双重抗HER2治疗

Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer

著录项

相似文献

相关主题

期刊订阅